Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands

INTRODUCTION: Infliximab is registered for the treatment of moderate-to-severe active ulcerative colitis (UC) adult patients who have had an inadequate response, or are intolerant, or have medical contraindications to therapy including corticosteroids and 5-aminosalicylates or thiopurines (6-mercapt...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhary, Mohammad A., Fan, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873082/
https://www.ncbi.nlm.nih.gov/pubmed/24392304
http://dx.doi.org/10.1007/s13554-012-0007-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873082/
https://www.ncbi.nlm.nih.gov/pubmed/24392304
http://dx.doi.org/10.1007/s13554-012-0007-0

Ejemplares similares